| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| VRP-1620 | VRP-1620 | Phase 3 Clinical | University Of Illinois | Breast Neoplasms | Details |
| Vodudeutentan | ENB-003; ENB-006 | Phase 2 Clinical | Enb Therapeutics Inc | Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| BQ-788 | BQ-788 | Phase 1 Clinical | Merck Serono | Cardiovascular Diseases; Hypertension; Melanoma | Details |
| GLX-002 | GLX-002; GLX002 | Phase 1 Clinical | Yabao Pharmaceutical Co Ltd Beijing | Pulmonary Arterial Hypertension | Details |
| Bosentan Orally Disintegrating Tablets(Beijing Sunho Pharma) | Phase 1 Clinical | Beijing Sunho Pharmaceutical Co Ltd | Pulmonary Arterial Hypertension | Details |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Sovateltide | IRL-1620; PMZ-1620; SPI-1620 | Approved | University Of Illinois At Chicago | Tyvalzi | India | Stroke | Pharmazz Inc | 2023-05-31 | Alzheimer Disease; Asphyxia Neonatorum; Biliary Tract Neoplasms; Brain Diseases; Brain Ischemia; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cerebral Infarction; Dementia; Ischemic Stroke; Spinal Cord Injuries; Stroke | Details |
| Macitentan/Tadalafil | Approved | Actelion Pharmaceuticals Ltd | OPSYNVI, Yuvanci | United States | Pulmonary Arterial Hypertension | Actelion Pharmaceuticals Us Inc | 2024-03-22 | Phenylketonurias; Pulmonary Arterial Hypertension | Details | |
| Bosentan Hydrate | ACT-050088; HGP-1206; Ro-47-0203; Ro-47-0203/029; Ro-47-0203/039 | Approved | F. Hoffmann-La Roche Ltd | Stayveer, 全可利, Tracleer | United States | Pulmonary Arterial Hypertension | Actelion Pharmaceuticals Ltd | 2001-11-20 | Anemia, Sickle Cell; Chronic thromboembolic pulmonary hypertension; Coronary Vasospasm; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fibrosis; Giant Cell Arteritis; Glaucoma; Heart Defects, Congenital; Heart Septal Defects, Atrial; Hepatopulmonary Syndrome; Hypertension; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Liver Cirrhosis; Lung Diseases, Interstitial; Persistent Fetal Circulation Syndrome; Pulmonary Arterial Hypertension; Pulmonary Fibrosis; Sarcoidosis; Scleroderma, Systemic; Sleep Apnea Syndromes; Takayasu Arteritis; Ulcer; Vasculitis | Details |
| Macitentan | ACT-064992; Actelion-1; JNJ-67896062 | Approved | Actelion Pharmaceuticals Ltd | Zependo, Opsumit, 傲朴舒 | United States | Pulmonary Arterial Hypertension | Actelion Pharmaceuticals Us Inc | 2013-10-18 | Anemia, Sickle Cell; Angina Pectoris; Chronic Disease; Chronic thromboembolic pulmonary hypertension; Eisenmenger Complex; Glioblastoma; Heart Defects, Congenital; Heart Failure; Heart Failure, Diastolic; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Pulmonary Arterial Hypertension; Pulmonary Embolism; Scleroderma, Systemic; Scleroderma-associated interstitial lung diseases; Thromboembolism; Ulcer | Details |
| Aprocitentan | ACT-132577; AC-080; JNJ-2820 | Approved | Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd | TRYVIO, JERAYGO | United States | Hypertension | Idorsia Pharmaceuticals Ltd | 2024-03-19 | Essential Hypertension; Hepatic Insufficiency; Hypertension; Renal Insufficiency, Chronic | Details |